Cardiac and cerebral manifestations in patients with antiphospholipid syndrome;Kardiale und zerebrale manifestationen bei antiphospholipid-syndrom

Zeitschrift fur Kardiologie

Volumn 91, Issue 8, 2002, Pages 650-658

  Jung, F ^a   Miesbach, W ^a   Scharrer, I ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Antiphospholipid syndrome; Cerebral manifestations; Coronary artery disease; Myocardial infarction; Valvular disease

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AORTA VALVE DISEASE; ARTICLE; BLOOD VESSEL OCCLUSION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL ARTICLE; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY DISEASE; FEMALE; HEART DISEASE; HEART INFARCTION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MITRAL VALVE DISEASE; NEUROLOGIC DISEASE; RIGHT CORONARY ARTERY; STENOSIS;

ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL HEMORRHAGE; CEREBRAL INFARCTION; CORONARY ANGIOGRAPHY; CORONARY THROMBOSIS; DEMENTIA; FEMALE; FOLLOW-UP STUDIES; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0036676076     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-002-0819-x     Document Type: Article

References (32)

1. Criteria for the diagnosis of lupus anticoagulants: An update
2. Antiphospholipid antibody syndrome
3. Immunology and clinical importance of antiphospholipid antibodies
4. Vascular disease in the antiphospholipid syndrome: A comparison with the patient population with atherosclerosis
5. HLA-DR antigens and anticardiolipin antibodies
6. Cardiac involvement in connective tissue diseases and primary antiphospholipid syndrome: Echocardiographic assessment and correlation with antiphospholipid antibodies
7. Primary antiphospholipid syndrome and cardiovascular disease
8. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA
9. Right ventricular thrombus after pacemaker implantation in a patient with secondary antiphospholipid syndrome
10. Valvular heart disease in the primary antiphospholipid syndrome
11. Neurological aspects of antiphospholipid antibody syndrome
12. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome
13. Hughes syndrome: Antiphospholipid syndrome
14. Fatal cerebral venous thrombosis as the initial manifestation of the antiphospholipid syndrome
15. Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood
16. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children
17. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: Association with antiphospholipid antibodies
18. The catastrophic antiphospholipid syndrome 1996: Acute multi-organ failure associated with antiphospholipid antibodies: A review of 31 patients
19. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies - A crucial role for acquired free protein S deficiency
20. Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome
21. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men
22. Antibodies to cardiolipin in young survivors of myocardial infarction: An association with recurrent cardiovascular events
23. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke
24. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies
25. Valvular heart disease in primary antiphospholipid syndrome (PAPS): Clinical and morphological findings
26. The antiphospholipid syndrome
27. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke
28. Anticardiolipin antibody and stroke: Possible relation of valvular heart disease and embolic events
29. Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death
30. Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: The WAPS project
31. The feasibility of a collaborative double-blind study using an anticoagulant